Drug resistance interpretation: PR HVDB 9.5.1 (2023-11-05)

PI Major Mutations: None PI Accessory Mutations: None

L10V ms. + 113V ms. + G16E ms. + K20R ms. + E35D ms. + M36I ms. + P39S ms. + R41K ms. + K45KR ms. + k57K ms. + L63LT ms. + H69K ms. + K70KR ms. + k59M ms.

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible Susceptible fosamprenavir/r (FPV/r) indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saguinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

PR comments

PR Other Mutations:

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- . K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

NRTI Mutations: M184MV variable into

NNRTI Mutations: None

RT Other Mutations: V211 stor. + K32K1 stor. + K32K1 stor. + Carrier + V35R stor. +

Nucleoside Reverse Transcriptase Inhibitors Non-nucleoside Reverse Transcriptase Inhibitors Low-Level Resistance doravirine (DOR) Susceptible abacavir (ABC) zidovudine (AZT) Susceptible efavirenz (EFV) Susceptible stavudine (D4T) Susceptible etravirine (ETR) Susceptible didanosine (DDI) nevirapine (NVP) Potential Low-Level Resistance Susceptible emtricitabine (FTC) High-Level Resistance rilpivirine (RPV) Susceptible lamivudine (3TC) High-Level Resistance

RT comments

NRTI

tenofovir (TDF)

M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

Other

. V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

Orug resistance mutation scores of NRTI:					Download CSV		
Rule	ABC ÷	AZT ≑	D4T ÷	DDI ≑	FTC ÷	зтс ≑	TD
M184MV	15	-10	-10	10	60	60	-1

Susceptible

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN


HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None INSTI Accessory Mutations: None

IN Other Mutations: \$17N wm . • 041N xm . • 050M wm . • 172V wm .

Integrase Strand Transfer Inhibitors

bictegravir (BIC) Susceptible
cabotegravir (CAB) Susceptible
dolutegravir (DTG) Susceptible
elvitegravir (EVG) Susceptible
raltegravir (RAL) Susceptible



Mutation scoring; IN

No drug resistance mutations were found for INISTI.